Potential Treatment Options for Patients With Relapsed Multiple Myeloma Following CAR T-Cell Therapy

Diabetes May Accelerate Blood Cancer Growth, Yet Survival Outcomes Differ by Race

Myeloma Patients Who Relapse After CAR T-Cell Therapy Have Options

Study shows encouraging therapeutic options for patients with relapsed multiple myeloma

Mount Sinai Researchers Report Encouraging Immunotherapy Option for Relapsed Myeloma Patients

Study Identifies Three-Gene Signature That May Predict Response to Selinexor in Patients With Multiple Myeloma

Blood-Based PD-L1 Tracking Could Offer Improved Response Prediction for Lung Cancer Immunotherapy

Third Dose of COVID-19 Vaccine Significantly Increases Immune Responses in Most Patients With Multiple Myeloma

Potentially Serious Side Effect Seen in Patient after Immunotherapy

Cancer Patients With Poor Antibody Response to COVID-19 Vaccines Also Lack Secondary Immune Response, Study Shows

"How Mount Sinai Health System Fosters Collaboration To Fight Cancer" - Joel Dudley, PhD and Samir Parekh, PhD